Sophia GeneticsFRA:90B +1.22%72 Market Cap is €441.28 Mil as of Jun. 30, 2026. GuruFocus rates FRA:90B with a GF Score™ of 72/100 and a GF Value™ of €4.30 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 694 Healthcare Providers & Services companies, Sophia Genetics ranks better than 71.61% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Sophia Genetics's share price for the quarter that ended in Mar. 2026 was €4.06. Sophia Genetics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 71.79 Mil. Therefore, Sophia Genetics's market cap for the quarter that ended in Mar. 2026 was €291.47 Mil.
Sophia Genetics's quarterly market cap
increased
from Sep. 2025 (€253.75 Mil) to Dec. 2025 (€265.73 Mil) and
increased
from Dec. 2025 (€265.73 Mil) to Mar. 2026 (€291.47 Mil).
Sophia Genetics's annual market cap
declined
from Dec. 2023 (€281.80 Mil) to Dec. 2024 (€212.06 Mil) but then
increased
from Dec. 2024 (€212.06 Mil) to Dec. 2025 (€265.73 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Sophia Genetics's Enterprise Value for Today is €438.68 Mil.
Sophia Genetics (FRA:90B) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Sophia Genetics Market Cap Related Terms
Sophia Genetics Market Cap Historical Data
* Premium members only.
The historical data trend for Sophia Genetics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Sophia Genetics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sophia Genetics Market Cap vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sophia Genetics's Market Cap distribution charts can be found below:
* The bar in red indicates where Sophia Genetics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Sophia Genetics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sophia Genetics (FRA:90B) has a Market Cap of €441.28 Mil as of Jun. 30, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Sophia Genetics and its competitors. According to the industry distribution chart, Sophia Genetics ranks #197 out of 694 companies in the Healthcare Providers & Services industry, placing it in the top 28.4%.
Is Sophia Genetics' Market Cap too high?
Sophia Genetics' current Market Cap is €441.28 Mil. Based on the distribution chart, Sophia Genetics ranks #197 out of 694 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Sophia Genetics has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sophia Genetics' Market Cap compare to WEAV and NRC?
According to the Healthcare Providers & Services industry distribution chart, Sophia Genetics ranks #197 out of 694 companies for Market Cap. This puts Sophia Genetics in the upper half of its industry. The industry median Market Cap is 93.08. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Healthcare Providers & Services company?
The median Market Cap among Healthcare Providers & Services companies is 93.08, based on 694 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Sophia Genetics and its competitors. For the Healthcare Providers & Services industry, the median Market Cap is 93.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sophia Genetics's current Market Cap is €441.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sophia Genetics stock overvalued right now?
Based on GuruFocus' analysis, Sophia Genetics (FRA:90B) is currently considered Modestly Overvalued. The stock's GF Value™ is €4.30, compared to a current price of €4.98 — trading 15.8% above its estimated fair value. The current Market Cap is €441.28 Mil. Sophia Genetics' overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Sophia Genetics (FRA:90B), the current Market Cap is €441.28 Mil as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sophia Genetics (FRA:90B) Overvalued in 2026?
Based on GuruFocus' analysis, Sophia Genetics stock appears to be overvalued.
The current stock price of €4.98 is trading 15.8% above its estimated GF Value™ of €4.30.
GuruFocus considers Sophia Genetics to be Modestly Overvalued.
Key valuation signals for FRA:90B:
Market Cap: €441.28 Mil
GF Value™: €4.30 vs. price of €4.98 (15.8% above fair value)
No single metric tells the full story. See the FRA:90B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
72GF Score
Get the complete analysis for FRA:90B
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:90B has been successfully added to your 
